Characterization of monoclonal antibody recognizing ERCC1 overexpression, a potential biomarker for cisplatin response

被引：0
|
作者：
Oishi, Takayuki [1 ]
Sasaki, Yuka [2 ]
Tong, Ying
Chen Lichao
Onodera, Takae [2 ]
Iwasa, Satoru
Udo, Emiko
Furusato, Bungo
Nakao, Kazuhiko
Yamada, Yasuhide
Hiraoka, Nobuyoshi
Masutani, Mitsuko [2 ]
机构：
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Genom Biomed, Nagasaki, Japan
[2] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol & Genom BioMed, Nagasaki, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PJ17-2-3
引用
收藏
页码：915 / 915
页数：1
相关论文
共 50 条
  • [1] Establishment of monoclonal antibody to detect ERCC1 overexpression, a possible biomarker for cisplatin resistance
    Oishi, Takayuki
    Sasaki, Yuka
    Furusato, Bungo
    Iwasa, Satoru
    Nakao, Kazuhiko
    Yamada, Yasuhide
    Hiraoka, Nobuyoshi
    Masutani, Mitsuko
    CANCER SCIENCE, 2018, 109 : 603 - 603
  • [2] Development of antibodies for detection of ERCC1 overexpression, a possible biomarker for cisplatin resistance of cancer
    Oishi, Takayuki
    Sasaki, Yuka
    Fujimori, Hiroaki
    Shibata, Noriko
    Iwasa, Satoru
    Nakao, Kazuhiko
    Yamada, Yasuhide
    Hiraoka, Nobuyoshi
    Masutani, Mitsuko
    CANCER SCIENCE, 2018, 109 : 1148 - 1148
  • [3] ERCC1 isoform expression levels characterized using a monoclonal antibody to ERCC1 and drug sensitivity
    Hayashi, Kohei
    Tong, Ying
    Oishi, Takayuki
    Chen, Lichao
    Sasaki, Yuka
    Onodera, Takae
    Yanagihara, Kazuyoshi
    Nakao, Kazuhiko
    Yamada, Yasuhide
    Masutani, Mitsuko
    CANCER SCIENCE, 2022, 113 : 1206 - 1206
  • [4] A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer
    Oishi, Takayuki
    Sasaki, Yuka
    Tong, Ying
    Chen, Lichao
    Onodera, Takae
    Iwasa, Satoru
    Udo, Emiko
    Furusato, Bungo
    Fujimori, Hiroaki
    Imamichi, Shoji
    Honda, Takuya
    Bessho, Tadayoshi
    Fukuoka, Junya
    Ashizawa, Kazuto
    Yanagihara, Kazuyoshi
    Nakao, Kazuhiko
    Yamada, Yasuhide
    Hiraoka, Nobuyoshi
    Masutani, Mitsuko
    GLOBAL HEALTH & MEDICINE, 2021, 3 (04): : 226 - 235
  • [5] ERCC1 and response to chemotherapy
    Soria, J. -C.
    EJC SUPPLEMENTS, 2007, 5 (08): : 15 - 15
  • [6] Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression
    Fuereder, Thorsten
    Stift, Judith
    Kuehrer, Irene
    Stranzl, Nadja
    Hoeflmaye, Doris
    Kornek, Gabriela
    Scheithauer, Werner
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 (10) : 958 - 964
  • [7] Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer
    Steffensen, K. D.
    Waldstrom, M.
    Jeppesen, U.
    Brandslund, I.
    Jakobsen, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (04) : 702 - 710
  • [8] Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer
    Steffensen, K. D.
    Waldstrom, M.
    Jeppesen, U.
    Brandslund, I.
    Jakobsen, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer
    Waldstrom, M.
    Steffensen, K. D.
    Jeppesen, U.
    Brandslund, I.
    Jakobsen, A.
    APMIS, 2008, 116 (03) : 239 - 240
  • [10] The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
    Obiedat, Hadeel
    Alrabadi, Nasr
    Sultan, Eyad
    Al Shatti, Marwa
    Zihlif, Malek
    BMC MEDICAL GENETICS, 2018, 19
12345